Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – Here’s What Happened

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price reached a new 52-week low during trading on Monday . The company traded as low as $22.22 and last traded at $21.90, with a volume of 216488 shares trading hands. The stock had previously closed at $23.77.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, JMP Securities reiterated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Price Performance

The business has a fifty day simple moving average of $27.37 and a 200 day simple moving average of $34.02. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -28.42 and a beta of -2.75.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Deep Track Capital LP grew its holdings in shares of Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after buying an additional 1,579,492 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Structure Therapeutics by 196.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock valued at $54,348,000 after acquiring an additional 820,589 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after acquiring an additional 602,609 shares during the last quarter. Vestal Point Capital LP lifted its stake in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $13,560,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.